Ionis Pharmaceuticals (NASDAQ: IONS) EVP sells 10,602 shares under 10b5-1 plan

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Ionis Pharmaceuticals EVP Research Eric Swayze reported an open-market sale of company stock. On June 25, 2026, he sold 10,602 shares of Common Stock at a weighted average price of $79.1824 per share in a transaction coded as an open-market sale.

The sale was executed under a Rule 10b5-1 trading plan adopted on March 6, 2026, indicating it was pre-arranged rather than opportunistic. Following the sale, Swayze directly held 21,759 shares of Ionis Pharmaceuticals common stock, and an additional 318 shares were reported as indirectly owned through his son.

Insider Trade Summary 10b5-1

Net Seller: 10,602 shares ($839,492)

Net Sell 2 txns

Insider Swayze Eric

Role EVP Research

Sold 10,602 shs ($839K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,602	$79.1824	$839K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 21,759 shares (Direct, null); Common Stock — 318 shares (Indirect, by Son)

Footnotes (1)

Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 6, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.00 to $79.46 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

Key Figures

Shares sold: 10,602 shares Weighted average sale price: $79.1824 per share Direct holdings after sale: 21,759 shares +3 more

6 metrics

Shares sold 10,602 shares Open-market sale on June 25, 2026

Weighted average sale price $79.1824 per share Common Stock sale on June 25, 2026

Direct holdings after sale 21,759 shares Common Stock directly owned after June 25, 2026 sale

Indirect holdings by son 318 shares Common Stock reported as indirectly owned through son

Rule 10b5-1 plan adoption date March 6, 2026 Trading plan governing June 25, 2026 sale

Intra-day sale price range $79.00–$79.46 per share Price range for multiple trades comprising reported sale

Key Terms

Rule 10b5-1 Trading Plan, weighted average price, open-market sale, Common Stock

4 terms

Rule 10b5-1 Trading Plan regulatory

"Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 6, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/26/2026 - 07:10 PM Accepted by SEC EDGAR 06/26/2026 - 07:09 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Swayze Eric

(Last)

(First)

(Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD

CALIFORNIA

92010

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP Research

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/25/2026		S		10,602⁽¹⁾	D	$79.1824⁽²⁾	21,759	D
Common Stock								318	I	by Son

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 6, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.00 to $79.46 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

	By: Patrick R. O'Neil, attorney-in-fact For: Eric Swayze	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Ionis Pharmaceuticals (IONS) report for Eric Swayze?

Ionis Pharmaceuticals reported that EVP Research Eric Swayze sold 10,602 shares of Common Stock. The sale occurred on June 25, 2026 at a weighted average price of $79.1824 per share in an open-market transaction coded as a sale.

At what price did Eric Swayze sell Ionis Pharmaceuticals (IONS) shares?

Eric Swayze’s 10,602-share sale used a weighted average price of $79.1824. Footnotes state the shares were sold in multiple trades between $79.00 and $79.46, all on June 25, 2026, under a pre-arranged Rule 10b5-1 plan.

How many Ionis Pharmaceuticals (IONS) shares does Eric Swayze hold after this Form 4?

After the reported sale, Eric Swayze directly holds 21,759 shares of Ionis Pharmaceuticals Common Stock. The filing also shows 318 additional shares reported as indirectly owned through his son, reflecting both direct and family-related holdings after the transaction.

Was Eric Swayze’s Ionis Pharmaceuticals (IONS) stock sale under a Rule 10b5-1 plan?

Yes. A footnote explains the 10,602-share sale was made under a Rule 10b5-1 trading plan. The plan was adopted on March 6, 2026, indicating the trades were pre-scheduled rather than timed in response to short-term market developments.

What does the weighted average price mean in the Ionis (IONS) Form 4 filing?

The weighted average price of $79.1824 reflects multiple individual trades between $79.00 and $79.46. The filing notes that detailed breakdowns of share counts at each specific price level are available upon request to the company, its security holders, or SEC staff.